Sobi, Savient (SVNT) Enter Kineret Co-Promotion Agreement

February 19, 2013 8:32 AM EST Send to a Friend
Sobi and Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that they have entered into an agreement for the co-promotion of Kineret® (anakinra) in the U.S.

Kineret, a recombinant IL-1 receptor antagonist, is a treatment for rheumatoid arthritis (RA) and indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active RA in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs). Kineret is also indicated in the U.S. for the treatment of children and adults with the severe form of Cryopyrin-Associated Periodic Syndromes (CAPS) called Neonatal-Onset Multisystem Inflammatory Disease (NOMID).

Savient is a specialty biopharmaceutical company that has developed and commercialized KRYSTEXXA® (pegloticase) for the treatment of refractory chronic gout in the U.S. Savient's specialized sales force has strong, established relationships with rheumatologists in the U.S., making Savient an excellent partner for Sobi.

Under the terms of the agreement, Sobi has granted to Savient the exclusive right to co-promote the sale of Kineret with Sobi in the U.S. Savient will market and promote Kineret beginning April 1, 2013. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety, and regulatory activities.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment